Excite Medical DRX9000 channel tops 20,000 subscribers amid global expansion

Excite Medical said its DRX9000 educational YouTube platform has passed 20,000 subscribers and 7.8 million lifetime views as the company expands regulatory access for its DRX9000-SL device in Canada, Saudi Arabia and Australia. The milestone comes alongside new research activity and a larger push to educate physicians and patients on non-surgical spinal decompression.

Why it matters: - Excite Medical is pairing education, research and regulatory wins to expand global awareness of non-surgical spinal decompression. - The company’s DRX9000 platform has become a broad-reaching channel for patients and physicians looking at conservative options for low back pain, sciatica and disc-related conditions. - The channel’s growth also signals rising interest in evidence-based alternatives before patients move to injections, opioids or spine surgery.

What happened: - Excite Medical said its official DRX9000 educational platform surpassed 20,000 YouTube subscribers and 7.8 million video views. - The platform launched in 2011 and is focused exclusively on non-surgical spinal decompression education. - Saleem Musallam, founder and CEO of Excite Medical, said the milestone shows growing worldwide demand for evidence-based education on conservative treatment options. - The platform’s content reaches audiences across North America, Europe, Asia, the Middle East, Australia and Latin America.

The details: - The channel includes physician testimonials, patient education, animated spinal anatomy, treatment demonstrations and clinical research. - Several videos have each surpassed 1 million views. - Excite Medical said the platform now ranks among the largest educational libraries dedicated exclusively to spinal decompression. - Within the past year, the DRX9000-SL True Non-Surgical Spinal Decompression System received regulatory clearance in Canada, Saudi Arabia and Australia. - The Australian Therapeutic Goods Administration included the DRX9000-SL in the Australian Register of Therapeutic Goods, allowing it to be supplied in Australia as a Class IIa medical device. - Excite Medical said those clearances reflect investment in engineering, software development, quality systems, international regulatory compliance and product innovation. - The DRX9000 has been the subject of published research on clinical outcomes, imaging findings and neurological function. - An early study in Pain Practice reviewed 94 patients with chronic discogenic low back pain and reported substantial pain reductions after DRX9000 treatment. - Research in BMC Musculoskeletal Disorders found statistically significant increases in lumbar disc height and significant reductions in chronic low back pain. - Researchers from the University of South Florida published a multicenter retrospective study in Military Medicine that evaluated 267 patients at seven sites. - That study found 90.5% of patients experienced pain reduction, along with significant improvements in neurological function, reflexes, muscle strength, sensation and activities of daily living. - The investigators concluded non-surgical spinal decompression may be an effective first-line conservative treatment before injections, opioid medications or spine surgery. - Four DRX9000-SL systems are in use at the University of South Florida Morsani College of Medicine. - Two of those systems are dedicated to clinical research, and two are used to treat patients in the Department of Neurosurgery & Brain Repair. - The RESTORE Trial is now underway as a prospective, randomized, double-blinded study sponsored by the University of South Florida with Stanford University and the U.S. Army Medical Research and Development Command. - Researchers in the RESTORE Trial are evaluating DRX9000-SL effects using MRI imaging, biomechanics, neurological testing, spinal motion analysis and patient-reported outcomes. - Excite Medical said it plans to expand the platform with more content on clinical studies, engineering advances, physician training and emerging technologies.

Between the lines: - The milestone suggests Excite Medical is using media reach as part of a broader strategy to reinforce clinical credibility. - The combination of regulatory approvals and published studies gives the company more material to support international adoption. - Research activity at academic and military institutions may help the technology gain wider acceptance among clinicians who want more than marketing claims.

What's next: - Excite Medical expects to keep growing the platform with new educational videos and research-focused content. - The RESTORE Trial will be a key next checkpoint for the DRX9000-SL as researchers gather prospective clinical data. - Further adoption could follow if additional studies and regulatory progress continue to support the device’s use in conservative spine care.

The bottom line: - Excite Medical is turning its DRX9000 education channel into a global funnel for clinical education, research visibility and device expansion.